Moneycontrol PRO

business

Contract research to boost performance in FY13: Dishman

In an interview with CNBC-TV18, JR Vyas, MD of Dishman Pharma said the the contract research income is going to boost the company's performance through FY13.

first published: Aug 2, 2012 10:40 am

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347